<DOC>
	<DOCNO>NCT01038466</DOCNO>
	<brief_summary>The aim CHAT study ( `` An open-label , randomize Phase II study Herceptin ( trastuzumab ) , Taxotere® ( docetaxel ) Xeloda ( capecitabine ) combination , versus Herceptin ( trastuzumab ) plus Taxotere® ( docetaxel ) , patient advance and/or metastatic breast cancer overexpress HER2 '' ) test combination Trastuzumab Docetaxel without capecitabine first-line therapy HER2 positive locally advanced metastatic breast cancer . Overall Response Rate primary endpoint CHAT study . This study fail meet primary objective showing difference treatment group , equivalent high response rate Trastuzumab plus Docetaxel Trastuzumab , Docetaxel plus capecitabine arm . Secondary endpoint CHAT study Progression-Free-Survival , Time-to-Progression , Overall Survival , duration response safety profile . Whilst analysis exist data consistent improvement triplet therapy , interpretation compromise relatively short median follow-up 24 month . In hindsight statistical design flaw selection sub optimal primary endpoint consequently data collect analysed early relation time-dependent endpoint . Beyond CHAT permit capture mature data time-related endpoint . Time-to-Progression Overall Survival co-primary endpoint Beyond CHAT protocol . The impact treatment follow first progression , survival , explore . Time-to-Progression define time interval date randomisation occurrence progressive disease therapy accord RECIST criterion . Overall Survival define time date randomisation date death</brief_summary>
	<brief_title>Observation Only Study Involving Participants Enrolled CHAT Trial</brief_title>
	<detailed_description>The objective study gain mature data long-term efficacy combination Trastuzumab Docetaxel without capecitabine first-line therapy HER2 positive locally advanced metastatic breast cancer . The study also aim gain information additional treatment sequence used patient progress follow combination Trastuzumab Docetaxel without capecitabine first-line therapy HER2 positive locally advanced metastatic breast cancer . Overall Survival data patient progress follow combination Trastuzumab Docetaxel without capecitabine first-line therapy HER2 positive locally advanced metastatic breast cancer also analyse report .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>CHAT trial participant whose data use final data analysis CHAT study Any patient withdraw consent CHAT study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>CHAT</keyword>
	<keyword>breast cancer</keyword>
	<keyword>non interventional observational study</keyword>
</DOC>